TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · IEX Real-Time Price · USD
1.190
-0.040 (-3.25%)
Jun 13, 2024, 3:22 PM EDT - Market open

Company Description

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.

The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.

Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.

TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D.

Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

TransCode Therapeutics, Inc.
TransCode Therapeutics logo
Country United States
Founded 2016
IPO Date Jul 9, 2021
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Thomas A. Fitzgerald M.B.A.

Contact Details

Address:
6 Liberty Square, #2382
Boston, Massachusetts 02109
United States
Phone 857-301-6857
Website transcodetherapeutics.com

Stock Details

Ticker Symbol RNAZ
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001829635
CUSIP Number 89357L105
ISIN Number US89357L3033
Employer ID 81-1065054
SIC Code 2834

Key Executives

Name Position
Thomas A. Fitzgerald M.B.A. Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration and Director
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. Executive Chairman of the Board
Dr. Zdravka Medarova Ph.D. Co-Founder and Chief Scientific Officer
Dr. Anna Moore Ph.D. Co-Founder, Scientific Advisor and Member of Scientific Advisory Board
Susan Duggan M.B.A., R.N. Senior Vice President of Operations
Dr. Daniel R. Vlock M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jun 10, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 7, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 7, 2024 8-K Current Report
May 20, 2024 DEFR14A Filing
May 15, 2024 8-K Current Report
May 15, 2024 10-Q Quarterly Report
May 13, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 10, 2024 PRE 14A Other preliminary proxy statements
May 10, 2024 8-K Current Report
Apr 29, 2024 ARS Filing